Plavix Ineffectiveness for Some May Lead FDA to Update Drug Label

AboutLawsuits

Add Your Comments

Following new research which suggests Plavix may be ineffective in as many as 30% of heart patients with certain genetic factors, the FDA is considering updates to the drug’s warning label.

Plavix (clopidogrel bisulfate) is a widely used blood thinner prescribed to prevent blood clots and reduce the risk of heart attacks and strokes. It is currently ranked among the top selling drugs in the world, with as many as 25 million prescriptions written in 2007 in the United States alone.

Several recent studies, two of which were published in the New England Journal of Medicine and one that was published in the Lancet, suggest that Plavix may not work for all cardiac patients. A genetic abnormality could prevent the drug from reducing the risk of blood clots by interfering with the liver’s ability to process Plavix in the bloodstream.

Do You Know about…

Spinal Cord Stimulator lawsuits

Spinal cord stimulator lawsuits are being investigated for individuals who suffered unnecessary shocks, burns or other problems, often resulting in the need for additional surgery to remove the SCS.

Learn More
SEE IF YOU QUALIFY FOR COMPENSATION
Spinal-Cord-Stimulation-Lawsuit
Spinal-Cord-Stimulation-Lawsuit

Do You Know About…

Spinal Cord Stimulator lawsuits

Spinal cord stimulator lawsuits are being investigated for individuals who suffered unnecessary shocks, burns or other problems, often resulting in the need for additional surgery to remove the SCS.

Learn More
SEE IF YOU QUALIFY FOR COMPENSATION

Two of the studies indicate that Plavix may not work in about 30% of people with the mutated gene, and the third suggests that only about 5% may be impacted.

According to the Wall Street Journal, the FDA is considering an update to the warning label to include data on the genetic factors that may prevent the Plavix from working. However, the inconsistent finding of the three studies have complicated the process of re-labeling the drug.

Plavix is a critical medication for many patients, and it is one of only a handful of treatment options to prevent potentially life-threatening blood clots in high risk patients, such as those who have had a heart stent implanted to open a previously clogged artery.

Providing warnings about the genetic factors that may prevent Plavix from working is important, as it could result in heart patients having a heart attack of stroke even though they are taking the medication as directed. In addition, it could unnecessarily expose patients to risk of Plavix side effects, such as an increased risk of gastrointestinal bleeding, ulcers and a possible increase in the risk of heart attacks or strokes for those with high cholesterol or high blood pressure.

Tags: Drug Eluting Stent, Heart Attack, Plavix, Stent, Stroke

More Plavix Lawsuit Stories

2 Comments

Susan
My husband was on Plavix for about 18 months after having stents. It did not prevent clots from forming. He was hospitalized nearly a dozen times and during the heart cath the cardiologist would remove long blood clots. He actually put one in a specimen cup for me. It was over an inch long. My husband eventually died as a result of plavix’s ineffectiveness.
FDA Reviewing Side Effects of Plavix with Prilosec and Other Drugs : AboutLawsuits.com
[…] research has found that Plavix may be ineffective in as many as 30% of heart patients with certain genetic factors and the FDA indicates that some […]

This field is for validation purposes and should be left unchanged.

Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

MORE TOP STORIES

Nearly 4,000 Bard PowerPort Lawsuits Now Filed Amid Upcoming Bellwether Trials
C.R. Bard and its Becton Dickinson parent company face more than 3,700 Bard PowerPort lawsuits that claim the port catheters are defectively designed.
Dupixent CTCL Studies Highlighted Cancer Risks For Years Lawsuit
A Dupixent CTCL lawsuit indicates manufacturers have long known the eczema treatment was linked to an increased cancer risk, but failed to warn doctors or patients.
MORE ABOUT: DUPIXENT LAWSUIT
Abbott Continues to Oppose Spinal Cord Stimulator Lawsuit MDL, Despite Mounting Claims
Manufacturer wants the Judicial Panel on Multidistrict Litigation to reject a proposal by a group of plaintiffs to consolidate all federal Abbott spinal cord stimulator lawsuits.